NXL · Nexalin Technology, Inc. · Executive Compensation
$2.07
-0.07 (-3.27%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated these conditions and concluded that the Company does not currently have sufficient cash and cash equivalents to fund its anticipated operating requirements for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Accordingly, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$1.57M
Shares
734,547
Volume · Oct 20
248.27K
Avg daily vol (36 sessions)
1.82M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark White | Chief Executive Officer | $839,476 |
| David Owens | Chief Medical Officer | $500,677 |
| Carolyn Shelton | Senior Vice-President of Quality, Clinical and Regulatory | $391,180 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark White | Chief Executive Officer | $1,028,470 |
| David Owens | Chief Medical Officer | $873,140 |
| Carolyn Shelton | Senior Vice-President of Quality, Clinical and Regulatory | $288,034 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Marilyn Elson | Chief Financial Officer | $345,000 |
| Mark White | Chief Executive Officer | $191,292 |
| Michael Nketiah | Senior Vice President of Quality, Regulatory and Clinical Affairs | $32,080 |
| David Owens | Chief Medical Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark White | Chief Executive Officer | $584,132 |
| David Owens | Chief Medical Officer | $293,750 |
| Michael Nketiah | Senior Vice President of Quality, Regulatory and Clinical Affairs | — |
| Marilyn Elson | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Justin Van Fleet | Chief Financial Officer | Appointed | 2025-08-04 |
| Justin Van Fleet | Chief Financial Officer | Appointed | 2025-07-21 |
| Carolyn Shelton | Senior Vice President Quality, Regulatory and Clinical Affairs | Appointed | 2024-09-19 |
| Michael Nketiah | Senior Vice President of Clinical, Quality, & Regulatory Affairs | Resigned | 2024-07-30 |
| Marilyn Elson | Chief Financial Officer | Resigned | 2023-09-28 |
Leadership
- Mark White CEO, Board Member
- Justin Van Fleet CFO
- Alan Kazden Board Member
- Ben V. Hu Board Member
- David Owens Board Member
- Leslie Bernhard Board Member